Spiro-linked pyrrolidine-2,5-diones active as enzyme aldose reductase inhibitors
US4503066A · kind A · utility
12Cited by
4References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 11, 1982 |
| Grant date | Mar 5, 1985 |
| Priority date | — |
| Expiry date | May 11, 2002 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D311/84
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The invention provides various medical compositions for use in treating or preventing certain of the side effects of diabetes or galactosemia. The active ingredients are selected from a series of novel aldose reductase inhibitory spiro-linked pyrrolidine-2,5-diones of the general formula: ##STR1## or a pharmaceutically acceptable salt, or a non-toxic, biodegradable precursor thereof. Processes for the production of these compounds are also provided. A particular compound suitable for use as an active ingredient is spiro[pyrrolidine-3,9'-xanthene]-2,5-dione.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.